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Aims: The synthetic leukotriene B4 receptor type 2 (BLT2) agonist CAY10583 (CAY) accelerates wound healing
in diabetic mice by promoting keratinocyte migration. However, its effects on ﬁbroblast activity and
granulation are unknown. We investigated the mechanisms by which CAY promotes wound healing.
Methods: CAYwas applied to wounds on streptozotocin-induced diabetic rats, andwound closure, granulation
thickness, and epithelialization gaps were analyzed. BLT2 expression was examined by RT-PCR. Migration and
proliferation were studied by scratch assays and MTS assays. Keratinocyte supernatants with CAY were
applied to ﬁbroblasts, and cytokines were measured by enzyme-linked immunosorbent assays.
Results: CAY signiﬁcantly accelerated wound healing in diabetic rats (CAY, 78.05 ± 12.22% vs. control,
59.84 ± 11.09%; p = 0.0222), with increased re-epithelialization and granulation compared to controls. BLT2
was expressed in keratinocytes, but not in ﬁbroblasts. Keratinocyte treatment with the CAY supernatant
enhanced ﬁbroblast proliferation and migration (ﬁbroblast scratch closure: CAY, 75.95 ± 4.09% vs. control,
49.69 ± 4.49%; p b 0.0001). CAY-treated keratinocytes exhibited increased TGF-β1 and bFGF expression.
Conclusions: CAY directly promotes keratinocyte migration and indirectly enhances ﬁbroblast proliferation by
increasing keratinocyte production of TGF-β1 and bFGF, accelerating wound closure. CAY is a promising
pharmaceutical agent for diabetic wounds.
© 201 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
7    1. Introduction
Diabetes mellitus (DM) is reaching epidemic proportions world-
wide. The number of DM patients has increased dramatically over the
past two decades and is expected to reach more than 360 million by
2030 (Whiting, Guariguata, Weil, & Shaw, 2006). DM frequently leads
to endothelial dysfunction and impaired angiogenesis, resulting in
ischemic vascular diseases or impaired wound healing. Patients withrcial associations or ﬁnancial
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Inc. This is an open access article uDM develop foot ulcerations, among whom half develop infections
that require hospitalization and 1 in 5 require amputation (Lavery et
al., 2006; Pickwell et al., 2015). The pathophysiology of intractable
wounds in diabetes is multifactorial, involving atherosclerotic
peripheral arteries, endothelial cell dysfunction, glycosylation of
extracellular matrix proteins, and peripheral neuropathy. Impaired
barrier functions, vasoconstriction, decreased proliferation and
migration of keratinocytes and ﬁbroblasts, and reduced chemotaxis
and leukocyte adhesion are often implicated in DM (Xu & Zou, 2014).
Leukotriene B4 receptor type 2 (BLT2) agonists stimulate kerati-
nocyte migration and accelerate wound healing in diabetic mice (Liu
et al., 2014). BLT2 is primarily known as a low-afﬁnity receptor for
leukotriene B4 (LTB4). LTB4 activates phagocytic cells, differentiated T
cells, and dendritic cells via BLT1, a high-afﬁnity LTB4 receptor, and is
involved in inﬂammation and immune responses (Iizuka et al., 2010;
Izumi, Yokomizo, Igarashi, & Shimizu, 1999; Kamohara et al., 2000;
Yokomizo, Izumi, Chang, Takuwa, & Shimizu, 1997; Yokomizo, Kato,
Terawaki, Izumi, & Shimizu, 2000). BLT1 and BLT2 are primarily
expressed in epidermal keratinocytes and in small intestinal tissues innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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expressed primarily in the spleen, liver, ovary, and leukocytes, withweak
signals in other organs, such as the lung, thymus, and brain (Chiba et al.,
2016; Ishii et al., 2016; Wang, El-Maghraby, Turcotte, Rola-Pleszczynski,
& Stankova, 2015; Yokomizo, 2015). Similar to the pattern in mice, BLT2
mRNA is prominently detected in human epidermal keratinocytes, and
not in human dermal ﬁbroblasts (Liu et al., 2014). Iizuka et al. (2005)
reported that the synthetic BLT2-speciﬁc agonist 4′-{[pentanoyl(pheny-
l)amino]methyl}-1,1′-biphenyl-2-carboxylic acid (CAY) activates both
human and mouse BLT2. In 2008, 12(S)-hydroxyheptadeca-5Z,
8E,10E-trienoic acid (12-HHT), a byproduct of thromboxane A2 (TXA2)
biosynthesis, was reported as an endogenous high-afﬁnity ligand for
BLT2 (Okuno et al., 2008).
Liu et al. (2014) recently reported that BLT2 agonists accelerate
keratinocyte migration by stimulating nuclear factor (NF)-κB signal-
ing, which induces the expression of tumor necrosis factors (TNFs)
and metalloproteinases (MMPs). They established that the
wound-healing process is delayed in BLT2-knockout mice and
endogenous and synthetic BLT2 agonists promote diabetic and
non-diabetic wound healing by enhancing keratinocyte migration.
These results underscore the therapeutic potential of BLT2 agonists;
however, few studies have examined the effects of BLT2 agonists on
ﬁbroblast activity and wound healing efﬁcacy. To the best of our
knowledge, the study by Liu et al. (2014) is the only analysis of the
therapeutic efﬁcacy of CAY for wound healing in diabetic mice.
Furthermore, CAY is available in ointment form; topical therapies for
diabetic wounds are highly desirable, further highlighting the
potential beneﬁts of CAY (McCallon & Frilot, 2015; Motley, Gilligan,
Lange, Waycaster, & Dickerson, 2015).
In the present study, the therapeutic efﬁcacy of topically
administered CAY on full-thickness wounds was evaluated in diabetic
rats. Its effects on re-epithelialization, granulation, and ﬁbroblast and
keratinocyte activity were examined. Furthermore, we analyzed the
direct and indirect effects of CAY on ﬁbroblast activity.
2. Materials and methods
2.1. Animals
Lewis rats (6–9 weeks of age, 180–220 g) were purchased from
Japan SLC Inc. (Tokyo, Japan) and maintained under a 12-h light/12-h
dark cycle. Food and water were provided ad libitum. Diabetes was
induced by a single intraperitoneal injection of 65 mg/kg streptozo-
tocin (Sigma-Aldrich Co. Ltd., St. Louis, MO, USA) dissolved in 0.01 M
sodium citrate buffer (pH 4.5). At 24 h and 48 h after injection,
non-fasting blood glucose was measured using a glucometer (Sanwa
Kagaku Kenkyusho Co. Ltd., Nagoya, Japan) in samples obtained from
the tail vein, and rats with consecutive glucose values N350 mg/dL
were retained. After 4 weeks, the blood glucose of the selected rats
was measured, and the rats that maintained hyperglycemia were
considered diabetic and used as wound healing models. All animal
procedures were performed according to the guidelines of the
Juntendo University Animal Care and Use Committee.
2.2. Wound healing model
All procedures were performed on anesthetized animals after
dorsal hair was removed using a shaver (THRIVE®, Daito Electric
Machine Industry Co. Ltd., Osaka, Japan) and Nair™ hair removal
cream (Church & Dwight Co. Inc., Ewing, NJ, USA). Two round,
full-thickness skin defects 1.5 cm in diameter weremade in the dorsal
skin after cleaning with 10% Popiyodon solution (Yoshida Pharma-
ceutical Co. Ltd. Tokyo, Japan) and 75% alcohol on each rat. Four
intradermal India ink tattoos were made at 4 mm distance from the
border of each wound to evaluate skin contracture. A silicone ring
with a 2-cm inner diameter and 3.6-cm outer diameter was placedwith glue (Daiichi-Sankyo Co. Ltd., Tokyo, Japan) around each wound
and sutured with 4-0 nylon (Akiyama-seisakusyo Co. Ltd., Tokyo,
Japan) to minimize skin contracture. The synthetic BLT2 agonist
CAY10583 (CAY) (Cayman Chemical Co. Ltd., Ann Arbor, MI, USA) was
dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich Co. Ltd.) to
make the CAY solution (100 μM). The CAY solution was mixed with
white Vaseline (Wako Pure Chemical Industries Ltd., Osaka, Japan)
and applied to the wounds (n = 6) in the CAY group (ﬁnal CAY
concentration, 10 μM). The wounds (n = 6) in the control group
were topically treated with white Vaseline mixed with only DMSO at
the same concentration as that in the CAY group. All wounds were
covered with surgical dressing (Alcare Co. Ltd., Tokyo, Japan) and
Tegaderm ﬁlm (3 M, Maplewood, MN, USA). Dressings and medica-
tion were changed daily. Digital photographs of wounds were
obtained every two days (Canon Inc., Tokyo, Japan). The wound
area was measured with computer-assisted image analysis software
(BZ-II Analyzer; Keyence Co. Ltd., Osaka, Japan) and was calibrated by
calculating the percentage of the wound areawith respect to the inner
area of the silicone ring to correct for differences in magniﬁcation,
perspective, or parallax. The wound closure ratio was calculated on
days 0, 2, 4, 6, 8, 10, 12, and 14 using the following formula:
Wound closure %ð Þ¼ ½1−ð wound area of dayx
inner area of silicon ring of dayx
=
wound area of day0
inner area of silicon ring of day0
Þ  100:
2.3. Hematoxylin and eosin staining
Animals were sacriﬁced on post-operative day 14. Wound tissue
samples were collected, ﬁxed in 10% formalin solution (Wako Pure
Chemical Industries Ltd.), and embedded in parafﬁn. Sections (4 μm)
from the central areas of wounds were used for hematoxylin and
eosin (H–E) staining. For H–E-stained slides, photographs were
obtained by BZ-9000 microscopy (Keyence Co. Ltd.), and
re-epithelialization and granulation tissue formation were assessed
by measuring the epithelium gap and thickness of granulation,
respectively. For every slide, estimates of the thickest and thinnest
granulation tissues were obtained, and the average thickness of the
granulation tissue was calculated using computer-assisted image
analysis software (BZ-II Analyzer; Keyence Co. Ltd.). The epithelial gap
distance was obtained by measuring the distance of the two ends of
the epithelium tongue.
2.4. Keratinocyte and ﬁbroblast cultures
Primary rat keratinocytes and ﬁbroblasts were isolated from
newborn Lewis rats within 3 days. Rat keratinocytes were isolated
and cultured in rat keratinocyte culturemedium (Cell Application Inc.,
San Diego, CA, USA) following a previously published protocol (Lichti,
Anders, & Yuspa, 2008). Rat ﬁbroblasts were cultured in Dulbecco's
Modiﬁed Eagle Medium (Thermo Fisher Scientiﬁc Inc., Waltham, MA,
USA) containing 10% fetal bovine serum (FBS; Thermo Fisher Scientiﬁc
Inc.), 100 U/mL penicillin, and 100 mg/mL streptomycin in a
humidiﬁed incubator at 37 °C with a 5% CO2 atmosphere. Cells were
used between passages two and three.
2.5. Reverse transcription-polymerase chain reaction
Total RNA was prepared from cultured rat keratinocytes or
ﬁbroblasts, using TRIzol reagent (Thermo Fisher Scientiﬁc Inc.). RNA
was used for reverse transcription (RT) using the High Capacity
RNA-to-cDNA Kit (Applied Biosystems, Waltham, MA, USA). A BLT2
expression vector was used as a positive control. After the RT reaction,
Table 1
Composition and designations of treatment groups for keratinocyte and ﬁbroblas
scratch assays.
Group Designation Composition
1 CAY− Keratinocyte medium + 0.02% DMSO
2 CAY+ Keratinocyte medium + CAY (100 nM) + 0.02% DMSO
3 KCSCAY− Supernatant of CAY− group + DMSO + DMEM + FBS (1%)
4 KCSCAY+ Supernatant of CAY+ group + DMEM + FBS (1%)
5 KCMCAY− Keratinocyte medium + DMSO + DMEM + FBS (1%)
6 KCMCAY+ Keratinocyte medium + CAY (100 nM) + DMSO +
DMEM + FBS (1%)
CAY: CAY10583; DMEM: Dulbecco's modiﬁed Eagle's medium; DMSO: dimethy
sulfoxide; FBS: fetal bovine serum; KCS: keratinocyte culture suspension; KCM
keratinocyte culture medium; + and− depict presence or absence of CAY, respectively
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primer pairs targeting rat BLT2 (forward: 5′-CGT CTT TAC TGC GGG
TGATT-3′, reverse: 5′-TGC CCT GAC CCA CTA CTT TC-3′) or rat
glyceraldehyde 3-phosphate dehydrogenase (GAPDH—forward:
5′-GGC AAG TTC AAT GGC ACA GT-3′, reverse: 5′-TGG TGA AGA CGC
CAG TAG ACT C-3′). The PCR mixtures were incubated at 95 °C for
5 min (initial denaturation), followed by 35 ampliﬁcation cycles of
95 °C for 3 s (denaturation), 55 °C for 30 s (annealing), and 72 °C for
30 s (extension). The reaction products were analyzed by electro-
phoresis (100 V/30 m) on 2% agarose gels, stained with ethidium
bromide (Bio-Rad Laboratories Inc., Hercules, CA, USA), and visualized
under UV light. The sizes of the ampliﬁed fragments were determined
using a 100-bp DNA ladder (Takara Bio Inc.). The expected product
sizes for BLT2 and GAPDH were 155 bp and 151 bp, respectively.
GAPDH served as an internal control.
2.6. Conditioned medium of keratinocytes
Rat keratinocytes (3 × 106) were seeded on a 100-mmdish coated
with type I collagen (Corning Inc., Corning, NY, USA) and cultured in
10 mL of keratinocyte medium. After 48 h, the medium was replaced
with 10 mL of CAY+ keratinocyte medium (keratinocyte medium +
100 nM CAY + 0.02% DMSO) or CAY− keratinocyte medium
(keratinocyte medium + 0.02% DMSO). After another 48 h, the
CAY+ and CAY − keratinocyte supernatants were collected, centri-
fuged at 200×g and 4 °C for 5 min to remove cell debris, and stored at
−80 °C until the subsequent ﬁbroblast scratch assay and
enzyme-linked immunosorbent assay (ELISA) (Fig. S1).
2.7. Scratch assay
Rat keratinocytes and ﬁbroblasts were seeded on a 96-well
ImageLock tissue culture plate (Essen BioScience Inc., Ann Arbor, MI,
USA) and incubated in a standard CO2 incubator to form cell
monolayers. The 96-well-plates for keratinocytes were coated with
type I collagen (Corning Inc.). Fibroblast monolayers were starved by
culturing in 1% FBS for at least 12 h before scratches were made.
Wounds were made with a 96-well wound maker (Essen BioScience
Inc.). Each wound was washed twice with culture medium to remove
unattached cells. Photographs of wounds were obtained automati-
cally, using IncuCyte Zoom (Essen BioScience Inc.). A ﬁbroblast scratch
assaywas performed to investigate the effects of the direct application
of CAY on ﬁbroblasts. Rat ﬁbroblasts were seeded on a 6-well plate
(Corning Inc.) and incubated in a standard CO2 incubator to form a cell
monolayer. The cell monolayers were starved in 1% FBSmedium for at
least 12 h. The scratches were made with P1000 tips. After removing
the unattached cells, 1% FBS medium with various concentrations of
CAY (1 nm, 10 nm, 100 nm, and 1 μM) was applied to the scratches.
The wound closure ratio was estimated as the migration area using
computer-assisted image analysis software (BZ-II Analyzer; Keyence
Co. Ltd.). Keratinocyte scratch assays were divided into two groups:
CAY+ Group (keratinocyte medium + CAY (100 nM) + 0.02%
DMSO) and CAY− Group (keratinocyte medium + 0.02% DMSO).
Fibroblast scratches were divided into four groups to investigate the
indirect effects of CAY. Fibroblasts were treated with keratinocyte
culture suspension (KCS) or with keratinocyte culture medium
(KCM), with or without CAY. The composition and designations of
the different groups are presented in Table 1.
2.8. Cell proliferation assay
Proliferation of keratinocytes and ﬁbroblasts was evaluated by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-((4-sulfophenyl)-2H-tetrazolium) chloride (MTS) assays, using the
Cell Tilter 96 AQueous One Solution Cell Proliferation Assay Kit
(Promega Co. Ltd., Fitchburg, WI, USA) according to the manufac-t
l
:
.turer's protocol. Fibroblasts or keratinocytes (2 × 103) were seeded in
a 96-well plate, cultured for an additional 24 h, and allowed to attach.
For keratinocytes, 96-well plates were coated with collagen type I.
Keratinocytes were treated with KCM containing CAY at various
concentrations (1 nM, 10 nM, 100 nM, and 1 μM). In the control
group, cells were treated with KCM containing the same concentra-
tion of DMSO. After 96 h of incubation, 20 mL of One Solution Reagent
was added to each well of a 96-well assay plate containing the
samples in 100 mL of culture medium. The cells were incubated for an
additional 2 h at 37 °C in a humidiﬁed, 5% CO2 atmosphere. The
production of formazan by viable cells wasmeasured at an absorbance
of 490 nm in a 96-well plate reader. Cell proliferation was analyzed.
Fibroblasts were cultured with KCSCAY+, KCSCAY−, KCMCAY+, and
KCMCAY− for 24 h, and cell proliferation was evaluated.
2.9. ELISA
Transforming growth factor-β1 (TGF-β1), basic ﬁbroblast growth
factor (bFGF), vascular endothelial growth factor (VEGF), and
hepatocyte growth factor (HGF) contents were determined on KCM
using the Quantikine ELISA Kit (R&D Systems Inc., Minneapolis, MN,
USA) according to manufacturer's protocol. Colorimetric reactions
were read at 450 nm on a microplate reader (Molecular Devices LLC,
Sunnyvale, CA, USA). The samples used to detect the TGF-β1 content
were concentrated six-fold using an Ultra-0.5 Centrifugal Filter with a
molecular weight cutoff of 30 K (Merck Millipore Co. Ltd., Darmstadt,
Germany).
2.10. Statistical analysis
Data are presented as means ± SD. All statistical analyses were
performed using unpaired Student's t-tests (two groups) or one-way
ANOVA with post-hoc tests (for more than two groups). Signiﬁcance
was determined at p b 0.05. All statistical analyses were implemented
in Prism 5 (GraphPad Software Inc., La Jolla, CA, USA).
3. Results
3.1. Topical application of CAY accelerated in vivo wound healing
Therapeutic efﬁcacy of CAY for diabetic wounds was investigated
by monitoring wound closure kinetics in streptozotocin-induced
diabetic rats. The BLT2 agonist CAY (10 μM) was administered
topically to full-thickness wounds. Statistically signiﬁcantly greater
wound closure was evident in the CAY-treated group than in the
control group beginning at day 4 (p = 0.0407). Interestingly,
the difference in wound closure between the CAY-treated group and
the control group became more pronounced over time until day 10;
the difference was approximately 6% at day 4 and reached almost 20%
at day 8 (p = 0.0222). Notably, 100% closure was observed in the
Fig. 1. Topical CAY accelerates wound closure in diabetic rats. (A) Representative
images show wound healing in the CAY (10 μM) group and control group. Wounds
were photographed at the indicated times from day 0 to day 14. (B) A comparison of the
wound closure percentage between the CAY and control groups (n = 6 per group,
*p b 0.05). (Comparison of wound closure percentage on day 14 by Mann–Whitney U
test; all other comparisons, unpaired Student's t-tests).
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observed in the control group (p b 0.05) (Fig. 1).3.2. BLT2 is expressed only in rat keratinocytes and not in ﬁbroblasts
RT-PCR showed that BLT2 mRNA was only present in rat
keratinocytes, and not in ﬁbroblasts (Fig. S2).3.3. CAY promoted re-epithelialization and granulation
On day 14, wound tissue samples from the CAY and control groups
were harvested for H–E staining and the width of the epithelial gap
and granulation thickness were measured. The epithelial gaps of the
wounds in the control group were signiﬁcantly wider than those in
the CAY-treated group (p = 0.0021) (Fig. 2B). Furthermore, the
granulation tissues of the wounds in the CAY group were signiﬁcantly
thicker than those of the wounds in the control group (p = 0.0034)
(Fig. 2C). The observed enhanced granulation indicated a potential
effect of CAY on ﬁbroblast activity, even though BLT2mRNA was only
expressed in rat keratinocytes. Therefore, we assessed the in vitro
effect of CAY using scratch assays.3.4. Direct CAY application promoted wound closure via
keratinocyte migration
Keratinocyte migration was signiﬁcantly enhanced after CAY
treatment (Fig. 3A,B). The cell-free area was 90.63 ± 11.23% in
the CAY− group and decreased to 40.08 ± 12.21% (i.e., less than
50% that of the CAY− group) in the CAY+ group (p b 0.0001). The
effect of CAY on keratinocyte proliferation was assessed using an
MTS assay for various concentrations of CAY. No signiﬁcant effect
of CAY on keratinocyte proliferation was observed at any
concentration (Fig. S3), indicating that the CAY-induced enhance-
ment in scratch closure was mainly due to increased keratinocyte
migration.3.5. Direct application of CAY did not promote rat ﬁbroblast
scratch closure
BLT2 mRNA was detected in rat keratinocytes, but not in rat
ﬁbroblasts. However, signiﬁcantly higher granulation in the
CAY-treated group than the control group prompted us to investigate
other possible direct or indirect effects of CAY on ﬁbroblast
proliferation and/or migration. When we directly applied various
concentrations of CAY to rat ﬁbroblasts in scratch assays, no
signiﬁcant difference in the cell-free area was observed between the
control group and CAY-treated ﬁbroblasts for any CAY concentration
(Fig. S4), conﬁrming that CAY does not have a direct effect on rat
ﬁbroblasts.
3.6. Indirect application of CAY promoted rat ﬁbroblast scratch closure
by promoting proliferation
We hypothesized that CAY treatment had an effect on dermal
ﬁbroblast activity via indirect stimulation. To test this hypothesis, we
added the supernatant of keratinocytes treated with CAY (KCSCAY+)
to ﬁbroblasts for 96 h in a scratch assay. We found that ﬁbroblast
scratch closure was signiﬁcantly accelerated when the supernatant of
keratinocytes was treated with CAY; ﬁbroblast scratch closure was
75.95 ± 4.09% in the KCSCAY+ group, but just 49.69 ± 4.49% in the
KCSCAY− group (p b 0.0001) (Fig. 3C,D). Furthermore, there was no
statistically signiﬁcant difference between the ﬁbroblasts treated with
KCS not containing CAY (i.e., KCSCAY−) and KCM containing or not
containing CAY (i.e., KCMCAY+ or KCMCAY−). These results suggest
that only the supernatant of CAY-treated keratinocytes inﬂuenced
ﬁbroblast activity. To evaluate the indirect effect on ﬁbroblast
proliferation, we performed an MTS assay under the same conditions
used for the scratch assay. Fibroblast proliferation was signiﬁcantly
higher after treatment with KCSCAY+ than other treatments, but there
was no signiﬁcant difference in proliferation between the KCMCAY+,
KCMCAY−, and KCSCAY− groups (Fig. 4A).
3.7. TGF-β1 and bFGF levels increased in the supernatant of
CAY-treated keratinocytes
Increased ﬁbroblast proliferation and in vitro ﬁbroblast scratch
closure were only detected in the KCSCAY+ group. We performed
ELISA to measure the levels of ﬁbroblast-stimulating factors in the
supernatants of the CAY+ and CAY− groups. The levels of TGF-β1 and
bFGF were signiﬁcantly higher in the supernatant of the CAY + group
than in the supernatant of the CAY− group (p = 0.0158). However,
there was no signiﬁcant difference in the VEGF or HGF contents after
CAY treatment (VEGF, p = 0.8243; HGF, p = 0.9651) (Fig. 4B–E). This
increased abundance of TGF-β1 and bFGF in keratinocytes after CAY
treatment might explain the observed enhancement in ﬁbroblast
activity and granulation.
4. Discussion
Our results provide strong evidence that the synthetic BLT2
agonist CAY effectively promotes diabetic wound closure. It not only
stimulates re-epithelialization, but also signiﬁcantly increases gran-
ulation in anti-contracture wounds in diabetic rats. We noted
complete wound closure in CAY-treated diabetic wounds, and
conﬁrmed that BLT2 was expressed in rat keratinocytes, but not in
ﬁbroblasts. Our results also provide the ﬁrst evidence that CAY
indirectly stimulates ﬁbroblast activity by increasing the release of
TGF-β1 and bFGF in keratinocytes.
BLT2 is a low-afﬁnity receptor for an arachidonic acid-derived
inﬂammatory mediator, LTB4 (Chiba et al., 2016; Iizuka et al., 2010;
Ishii et al., 2016), but 12-HHT is currently considered as an
endogenous ligand for BLT2 (Okuno et al., 2008). Reduced 12-HHT
Fig. 2. Topical CAY promotes re-epithelialization and granulation formation. (A) Images
of hematoxylin and eosin (H–E)-stained wounds in the CAY group and the control
group (scale bar =1000 μm). (B) Comparison of the epithelial gap size using the H–E
slides. (C) Comparison of granulation tissue thickness measured from the H–E slides
(n = 6 per group,*p b 0.05. B, Mann–Whitney U test; C, unpaired Student's t-test).
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a critical role of the 12-HHT/BLT2 axis in cutaneous wound healing
(Iizuka et al., 2005; Liu et al., 2014). CAY is a synthetic BLT2 agonist
(Iizuka et al., 2005); in a mouse model, Liu et al. (2014) demonstrated
that CAY accelerates wound healing and endogenous 12-HHT plays an
important role. Notably, they concluded that CAY stimulates only the
migration of keratinocytes, which explains the observed therapeutic
efﬁcacy of CAY. Using a diabetic rat model and an in vitro scratch
wound model, this study provides new mechanistic insights into the
effect of CAY on diabetic wound healing. The most striking result of
the study is the indirect stimulation of ﬁbroblasts by CAY, which plays
a central role in enhancing granulation in the anti-contracture wound
and accelerating wound healing in diabetic rats. This ﬁnding has high
translational relevance, as human wound healing involves both
ﬁbroblast and keratinocyte activity during different phases of
wound healing and ﬁbroblast dysfunction is implicated in delayed
wound healing in human diabetes (Lerman, Galiano, Armour, Levine,
& Gurtner, 2003).We performed an extensive analysis of the migration and
proliferation of keratinocytes and ﬁbroblasts using scratch wound
healing assays and an MTS assay. CAY did not promote the closure of
rat ﬁbroblast scratch wounds, consistent with the observation that
BLT2 mRNA was only expressed in rat keratinocytes. However, this
result failed to explain the signiﬁcantly higher granulation observed
in CAY-treated wounds in diabetic rats. We therefore hypothesized an
indirect effect of CAY on ﬁbroblast activity. To test this hypothesis, we
applied the supernatant of CAY-treated rat keratinocytes to an in vitro
scratch model of rat ﬁbroblasts. We observed signiﬁcantly accelerated
wound healing when the supernatant of CAY-treated keratinocytes
was applied, while there was no effect of the keratinocyte supernatant
that lacked CAY. We further analyzed the effect of the keratinocyte
supernatant on ﬁbroblast proliferation, as both the migration and
proliferation of ﬁbroblasts contribute to wound healing. Based on the
MTS assay, the proliferation of ﬁbroblasts increased signiﬁcantly after
treatment with CAY-treated keratinocyte supernatants, conﬁrming
the indirect stimulation of ﬁbroblast activity by CAY (Fig. 4A).
To determine the factors underlying indirect stimulation, we
performed ELISA to examine the keratinocyte supernatant. We
detected an increased abundance of TGF-β1 and bFGF in the
keratinocyte supernatant treated with CAY. CAY treatment had no
effect on VEGF and HGF abundance in the keratinocyte supernatant.
TGF-β1 is involved in various temporal and spatial aspects of wound
healing, including cell differentiation regulation, collagen production,
and extracellular matrix degradation (Penn, Grobbelaar, & Rolfe,
2012). It induces ﬁbroblast proliferation and migration (He et al.,
2015; Liu, Liu, Shi, & Bao, 2016; Saito et al., 2012; Strutz et al., 2001).
Exogenous controlled delivery of TGF-β1 has been investigated
extensively and has therapeutic advantages (Anitua et al., 2008;
Reyes et al., 2014). We therefore believe that the CAY-induced
endogenous stimulation of TGF-β1 in keratinocytes has advantages in
terms of controlled ﬁbroblast proliferation and migration, granula-
tion, and wound healing, though further studies are needed to
elucidate the mechanism of TGF-β1 upregulation in keratinocytes and
its spatial or temporal effect on wound healing (Penn et al., 2012).
bFGF stimulates wound healing in both diabetic and non-diabetic
conditions (Yang et al., 2012); thus, its increased abundance in
CAY-treated keratinocytes is also expected to contribute to wound
closure, in addition to the direct effects of CAY on keratinocyte
migration and TGF-β1 abundance. Several previous studies have
shown that bFGF promotes ﬁbroblast proliferation and migration. The
exogenous administration of bFGF accelerates both normal and
diabetic rat skin repair (Losi et al., 2013; Yang et al., 2012). However,
owing to its short half-life, controlled bFGF delivery may maximize its
therapeutic advantages (Huang et al., 2016; Losi et al., 2013). CAY
increases the endogenous bFGF levels in keratinocytes and accord-
ingly it can overcome issues related to the bFGF half-life and
controlled release. However, the effects of bFGF are expected to be
multifactorial and further analyses are needed to understand the
precise role of CAY in increasing bFGF in keratinocytes and its
therapeutic role in wound healing. Since cutaneous wound healing in
diabetes involves a series of coordinated processes and ﬁbroblast
proliferation and migration play a critical role (Xuan et al., 2014), the
indirect stimulation of ﬁbroblasts via increases in TGF-β1 and bFGF in
CAY-treated keratinocytes likely contributes to the enhanced granu-
lation and accelerated wound healing (Lerman et al., 2003; Uchi et al.,
2009).
The beneﬁts and hazards of growth factors for foot ulcers in
patients with type 1 or type 2 DM were recently systematically
reviewed by Marti-Carvajal, Rojas-Reyes, Reveiz, Rodriguez-Malagon,
and Cedeno-Taborda (2015). Based on 28 randomized clinical trials
involving 2365 participants, the authors inferred that growth factors
might increase the likelihood of complete healing of foot ulcers in
people with diabetes. However, additional trials and experiments are
needed to establish the efﬁcacy and safety proﬁles of the growth
Fig. 3. CAY accelerates in vitro keratinocyte wound closure. (A) Primary cultured epidermal keratinocyte cultured to conﬂuence, mechanically wounded by scratching, and incubated
in medium for 96 h (n = 6 per group); the CAY+ group contained CAY (100 nM) and the CAY− group was the control. (B) Comparison of wound closure at 96 h (*p b 0.05). Indirect
application of CAY affects in vitro ﬁbroblast wound closure. Representative images (C) and percentage wound closure for the KCSCAY+, KCSCAY−, KCMCAY−, and KCMCAY+ groups
(n = 6 per group, *p b 0.05) (D).
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on keratinocytes or ﬁbroblasts; however, the toxicity and efﬁcacy
proﬁle of CAY in wound healing still need to be established.
Furthermore, although we demonstrated the therapeutic efﬁcacy of
CAY in diabetic rats, in vitro cell scratch assays do not reﬂect diabetic
conditions. Wound healing involves a sequence of complex biological
and molecular events, including cell migration, cell proliferation, and
extracellular matrix deposition; therefore, the mechanism of CAY
action warrants further scrutiny, with a focus on the complex
interactions between keratinocytes and ﬁbroblasts, the temporaland spatial aspects of wound healing, paracrine mediators, and
cellular dysfunction under diabetic conditions. Among the related
factors, the role of TGF-β1 in renal ﬁbrosis needs to be carefully
considered when designing therapeutic approaches for chronic
wound healing in diabetes. TGF-β1 is involved in the pathogenesis
of diabetic nephropathy, and TGF-β1 antagonists have been shown to
be effective for treating ﬁbrotic disorders. Conversely, TGF-β1
stimulation promotes wound healing, including in diabetic wounds
(Lan, 2012; Pakyari, Farrokhi, Maharlooei, & Ghahary, 2013; Roberts
et al., 1986). The precise role of TGF-β1 is still unclear; recent evidence
Fig. 4. MTS assay using rat ﬁbroblasts cultured with KCSCAY+, KCSCAY−, KCMCAY+, and
KCMCAY− for 24 h (n = 6 per group, *p b 0.05). CAY stimulates rat keratinocytes to
release TGF-β1 and bFGF. TGF-β1 (B), bFGF (C), VEGF (D), and HGF (E) levels in the
supernatant of keratinocytes stimulated with CAY (100 nM)measured by ELISA (n = 6
per group, *p b 0.05).
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but high expression exacerbates the condition in mice (Hathaway et
al., 2015). Endogenous production of TGF-β1 in keratinocytes after
topical administration of CAY is not expected to directly affect renal
ﬁbrosis under diabetic conditions; nevertheless, the potential of
TGF-β1 to induce diabetic nephropathy should be acknowledged
when implementing TGF-β1-based wound healing therapies. Fur-
thermore, in diabetes, multiple factors contribute to delayed wound
healing, in addition to TGF-β1 expression and ﬁbroblast activity. In
particular, oxidative stress in chronic wounds can lead to delayed
healing andmay be a crucial modulator of TGF-β1 signaling (Bagdas et
al., 2015; Richter & Kietzmann, 2016). Ciccone et al. (2013)
highlighted the role of dietary factors and stress on the free radical
scavenger properties of dietary carotenoids. These observations
emphasize the beneﬁcial effects of the dietary intake of antioxidants
on wound healing; accordingly, a multi-factorial approach may be
useful in chronic diabetic wound healing (Rasik & Shukla, 2000).
Despite these limitations, the results of this study and those of Liu
et al. (2014) highlight the therapeutic potential of CAY. This is the
second report of the efﬁcacy of CAY on diabetic wounds and the ﬁrst
report of the indirect stimulation of ﬁbroblasts by CAY. Previous
studies only demonstrated wound contracture, and did not report any
notable improvements in granulation in diabetic wounds (Liu et al.,2014). Importantly, the rat model used in this work closely mimics
clinical aspects of human wound healing (Galiano, Michaels,
Dobryansky, Levine, & Gurtner, 2004). We are currently exploring
additional factors related to clinical efﬁcacy in humans, the ease of
administration, and commercial feasibility of CAY ointments for
diabetic wound healing. We believe that the results of this study will
serve as a basis for designing future in vitro, animal, and human
experiments targeting the 12-HHT/BLT2 axis in diabetic cutaneous
wounds.5. Conclusions
This study conﬁrms the therapeutic efﬁcacy of the BLT2 agonist
CAY for wound healing. CAY enhanced re-epithelialization and
granulation in anti-contracture wounds in diabetic rats, leading to
complete wound closure. In an in vitro scratch assay, CAY stimulated
keratinocyte migration, but did not directly inﬂuence ﬁbroblast
activity. However, CAY enhanced ﬁbroblast proliferation and acceler-
ated scratch closure after treatment with a CAY-treated keratinocyte
supernatant. The CAY-treated keratinocyte supernatant contained
high levels of TGF-β1 and bFGF and indirectly stimulated ﬁbroblasts.
These results highlight the therapeutic potential of CAY in the
treatment of diabetic wounds. Further studies are needed to
understand the therapeutic efﬁcacy and safety proﬁle as well as to
clarify the mechanisms underlying the direct and indirect effects of
CAY.
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